Subscribe To
STOK / Wall Street Analysts See a 192% Upside in Stoke Therapeutics, Inc. (STOK): Can the Stock Really Move This High?
STOK News
By Seeking Alpha
September 10, 2023
Stoke Therapeutics Is Unable To Derisk Its Platform
Stoke Therapeutics (STOK) stock is down 40% after failing to meet expectations in a phase 1/2 epilepsy trial. STOK develops therapies for rare disease more_horizontal
By Zacks Investment Research
August 7, 2023
Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Lags Revenue Estimates
Stoke Therapeutics, Inc. (STOK) came out with a quarterly loss of $0.69 per share versus the Zacks Consensus Estimate of a loss of $0.65. This compare more_horizontal
By The Motley Fool
July 25, 2023
Why Shares of Stoke Therapeutics Plummeted Tuesday
Stoke Therapeutics' shares hit a 52-week low on Tuesday. The company is testing STK-001 to treat Dravet syndrome, a progressive genetic epilepsy disor more_horizontal
By Zacks Investment Research
June 21, 2023
Stoke Therapeutics, Inc. (STOK) Surges 6.3%: Is This an Indication of Further Gains?
Stoke Therapeutics, Inc. (STOK) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate re more_horizontal
By Zacks Investment Research
May 9, 2023
How Much Upside is Left in Stoke Therapeutics, Inc. (STOK)? Wall Street Analysts Think 102.91%
The consensus price target hints at a 102.9% upside potential for Stoke Therapeutics, Inc. (STOK). While empirical research shows that this sought-aft more_horizontal
By Zacks Investment Research
May 4, 2023
Stoke Therapeutics, Inc. (STOK) Reports Q1 Loss, Tops Revenue Estimates
Stoke Therapeutics, Inc. (STOK) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.70. This compare more_horizontal
By Zacks Investment Research
March 6, 2023
Stoke Therapeutics, Inc. (STOK) Reports Q4 Loss, Tops Revenue Estimates
Stoke Therapeutics, Inc. (STOK) delivered earnings and revenue surprises of 9.72% and 11.42%, respectively, for the quarter ended December 2022. Do th more_horizontal
By Seeking Alpha
February 12, 2023
Stoke Therapeutics Looks Unfairly Valued
STOK went down steadily over the past two years. Its derisking Dravet data did not help either. more_horizontal